Min-Max Optimal Design of Two-Armed Trials with Side Information

References

• Atkinson A (2015) Optimum designs for two treatments with unequal variances in the presence of covariates. Biometrika 102(2):494–499.Crossref, Google Scholar
• Berry DA (2006) Bayesian clinical trials. Nature Rev. Drug Discovery 5(1):27–36.Crossref, Google Scholar
• Berry DA, Mueller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M (2002) Adaptive Bayesian designs for dose-ranging drug trials. Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M, eds. Case Studies in Bayesian Statistics, Lecture Notes in Statistics, vol. 162 (Springer, New York), 99–181.Google Scholar
• Bertsimas D, Johnson M, Kallus N (2015) The power of optimization over randomization in designing experiments involving small samples. Oper. Res. 63(4):868–876.Link, Google Scholar
• Bhat N, Farias VF, Moallemi CC, Sinha D (2020) Near optimal A-B testing. Management Sci. 66(10):4477–4495.Link, Google Scholar
• ClinCalc (2016) Number of prescriptions over time. Accessed March 1, 2021, https://clincalc.com/DrugStats/Drugs/Warfarin.Google Scholar
• DeNegre S (2011) Interdiction and discrete bilevel linear programming. Unpublished doctoral thesis, Lehigh University, Bethlehem, PA.Google Scholar
• Fisher RA (1936) Design of experiments. BMJ 1(3923):554–554.Crossref, Google Scholar
• Giffin RB, Lebovitz Y, English RA, et al. (2010) Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary (National Academies Press, Washington, DC).Google Scholar
• Hayden E (2015) California unveils “precision-medicine” project. Nature News. https://www.nature.com/news/california-unveils-precision-medicine-project-1.17324.Google Scholar
• Kallus N (2018) Optimal a priori balance in the design of controlled experiments. J. Roy. Statist. Soc. Statist. Methodology Ser. B 80(1):85–112.Crossref, Google Scholar
• Kosorok MR, Laber EB (2019) Precision medicine. Annual Rev. Statist. Appl. 6:263–286.Crossref, Google Scholar
• Kotas J, Ghate A (2018) Bayesian learning of dose–response parameters from a cohort under response-guided dosing. Eur. J. Oper. Res. 265(1):328–343.Crossref, Google Scholar
• Laber EB, Zhao YQ, Regh T, Davidian M, Tsiatis A, Stanford JB, Zeng D, Song R, Kosorok MR (2016) Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy. Statist. Medicine 35(8):1245–1256.Crossref, Google Scholar
• Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J. National Cancer Inst. 101(10):708–720.Crossref, Google Scholar
• Majewski IJ, Bernards R (2011) Taming the dragon: Genomic biomarkers to individualize the treatment of cancer. Nature Medicine 17(3):304–312.Crossref, Google Scholar
• Morris M, Dean A, Stufken J, Bingham D (2015) History and overview of design and analysis of experiments. Handbook of Design and Analysis of Experiments (Chapman and Hall/CRC Press, Boca Raton, FL), 21–80.Google Scholar
• Pharmacogenetics Consortium (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. New England J. Medicine 360(8):753–764.Crossref, Google Scholar
• Press WH (2009) Bandit solutions provide unified ethical models for randomized clinical trials and comparative effectiveness research. Proc. Natl. Acad. Sci. USA 106(52):22387–22392.Crossref, Google Scholar
• Qian M, Murphy SA (2011) Performance guarantees for individualized treatment rules. Ann. Statist. 39(2):1180.Crossref, Google Scholar
• Rencher AC, Schaalje GB (2008) Linear Models in Statistics (John Wiley & Sons, New York).Google Scholar
• Schork NJ (2015) Personalized medicine: Time for one-person trials. Nature 520(7549):609–611.Crossref, Google Scholar
• Sertkaya A, Wong HH, Jessup A, Beleche T (2016) Key cost drivers of pharmaceutical clinical trials in the United States. Clinical Trials 13(2):117–126.Crossref, Google Scholar
• Shi C, Song R, Lu W, Fu B (2018) Maximin projection learning for optimal treatment decision with heterogeneous individualized treatment effects. J. Roy. Statist. Soc. Statist. Methodology Ser. B 80(4):681–702.Crossref, Google Scholar
• Singh M, Xie W (2020) Approximation algorithms for D-optimal design. Math. Oper. Res. 45(4):1512–1534.Link, Google Scholar
• Tang Y, Richard JPP, Smith JC (2016) A class of algorithms for mixed-integer bilevel min–max optimization. J. Global Optim. 66(2):225–262.Crossref, Google Scholar
• Tufts (2014) Cost to develop and win marketing approval for a new drug is $2.6 billion. Accessed March 1, 2021, http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study.Google Scholar
• White PJ (2010) Patient factors that influence warfarin dose response. J. Pharmacy Practice 23(3):194–204.Crossref, Google Scholar
• Wu CJ, Hamada MS (2011) Experiments: Planning, Analysis, and Optimization, vol. 552 (John Wiley & Sons, New York).Google Scholar
• Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch. Internal Medicine 167(13):1414–1419.Crossref, Google Scholar